HK1062923A1 - Igf-binding protein-derived peptide - Google Patents

Igf-binding protein-derived peptide

Info

Publication number
HK1062923A1
HK1062923A1 HK04105749A HK04105749A HK1062923A1 HK 1062923 A1 HK1062923 A1 HK 1062923A1 HK 04105749 A HK04105749 A HK 04105749A HK 04105749 A HK04105749 A HK 04105749A HK 1062923 A1 HK1062923 A1 HK 1062923A1
Authority
HK
Hong Kong
Prior art keywords
igf
binding protein
derived peptide
disease
new
Prior art date
Application number
HK04105749A
Other languages
English (en)
Inventor
Desmond Mascarenhas
Original Assignee
Bioexpertise Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioexpertise Llc filed Critical Bioexpertise Llc
Publication of HK1062923A1 publication Critical patent/HK1062923A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04105749A 2001-09-18 2004-08-04 Igf-binding protein-derived peptide HK1062923A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32326701P 2001-09-18 2001-09-18
PCT/US2002/025532 WO2003025121A2 (fr) 2001-09-18 2002-08-09 Peptide ou petite molecule derive de proteines de liaison de l'igf

Publications (1)

Publication Number Publication Date
HK1062923A1 true HK1062923A1 (en) 2004-12-03

Family

ID=23258422

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04105749A HK1062923A1 (en) 2001-09-18 2004-08-04 Igf-binding protein-derived peptide

Country Status (9)

Country Link
US (1) US6861406B2 (fr)
EP (1) EP1435986B1 (fr)
JP (1) JP4344242B2 (fr)
AT (1) ATE382364T1 (fr)
AU (1) AU2002324672B2 (fr)
CA (1) CA2460719A1 (fr)
DE (1) DE60224419D1 (fr)
HK (1) HK1062923A1 (fr)
WO (1) WO2003025121A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) * 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US20050244422A1 (en) * 2004-04-16 2005-11-03 Desmond Mascarenhas Methods for delivering MBD peptide-linked agent into cells under conditions of cellular stress
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
WO2005033132A2 (fr) * 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
US20060084603A1 (en) * 2004-08-06 2006-04-20 Irena Kirman IGF-BP3-related methods for inhibiting tumor growth
US9339403B2 (en) * 2004-11-12 2016-05-17 Icon Medical Corp. Medical adhesive for medical devices
US7455688B2 (en) * 2004-11-12 2008-11-25 Con Interventional Systems, Inc. Ostial stent
US20060198869A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Bioabsorable medical devices
WO2006110197A2 (fr) 2005-03-03 2006-10-19 Icon Medical Corp. Dispositif medical en polymere biodegradable
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
AU2006221046B2 (en) * 2005-03-03 2012-02-02 Icon Medical Corp. Improved metal alloys for medical device
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US7611893B2 (en) 2005-11-09 2009-11-03 Ontherix, Inc. Metal-binding therapeutic peptides
US7662624B2 (en) * 2005-11-09 2010-02-16 Ontherix, Inc. Metal-binding therapeutic peptides
AU2006311538A1 (en) * 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
US20080039393A1 (en) * 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
WO2008008291A2 (fr) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
WO2008086813A2 (fr) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides dérivés de protéines de la superfamille de l'insuline
US8536135B2 (en) * 2008-03-19 2013-09-17 Ontherix, Inc. Adaptive biochemical signatures
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
US11266767B2 (en) 2014-06-24 2022-03-08 Mirus Llc Metal alloys for medical devices
WO2017026505A1 (fr) * 2015-08-11 2017-02-16 池田食研株式会社 Agent de liaison
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
CN109071647B (zh) * 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5200509A (en) 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
DK0597033T3 (da) 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US5643867A (en) 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
AU674449B2 (en) 1993-08-03 1996-12-19 Celtrix Pharmaceuticals, Inc. Method of treating reproductive disorders
ES2241906T3 (es) 1993-09-20 2005-11-01 Celtrix Pharmaceuticals, Inc. Tratamiento de trastornos inmunologicos y hematologicos con igfbp solo o asociado con igf.
WO1995013823A1 (fr) 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Procede de traitement de troubles neurologiques
CA2176709A1 (fr) 1993-11-15 1995-05-26 Howard R. Higley Procede de traitment d'affections renales par administration de facteur de croissance insulinoide-i (igf-i) et de proteine-3 fixatrice du facteur de croissance insulinoide (igfbp-3)
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
CA2195474A1 (fr) 1994-07-20 1996-02-01 Cedo Martin Bagi Complexe igf/igfbp pour promouvoir la formation de tissu osseux et pour reguler le remodelage osseux
CA2232000A1 (fr) 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Proteine de liaison 3 du facteur de croissance insulinoide (igf-bp3) dans le traitement de tumeurs liees a p53
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
WO2000023469A2 (fr) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments
WO2001087238A2 (fr) 2000-05-17 2001-11-22 Oregon Health & Sciences University Induction de l'apoptose et inhibition de la croissance cellulaire par la proteine 4.33 (p4.33)
CA2422625A1 (fr) 2000-09-19 2002-03-28 Bioexpertise, Llc Utilisation de la proteine de liaison de l'igf pour la sensibilisation selective de cellules cibles in vivo
WO2002034916A2 (fr) 2000-10-27 2002-05-02 Oregon Health And Science University Nouvelles molecules igbp-3 mutantes qui ne se lient pas aux igf, mais qui conservent leur capacite de se lier fonctionnellement au recepteur d'igfbp-3
NZ526672A (en) 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
AU2002248609B2 (en) * 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides

Also Published As

Publication number Publication date
EP1435986A4 (fr) 2006-01-11
WO2003025121A2 (fr) 2003-03-27
DE60224419D1 (de) 2008-02-14
EP1435986B1 (fr) 2008-01-02
WO2003025121A3 (fr) 2004-01-22
CA2460719A1 (fr) 2003-03-27
JP2005504801A (ja) 2005-02-17
ATE382364T1 (de) 2008-01-15
US6861406B2 (en) 2005-03-01
US20030059430A1 (en) 2003-03-27
JP4344242B2 (ja) 2009-10-14
AU2002324672B2 (en) 2007-11-08
EP1435986A2 (fr) 2004-07-14

Similar Documents

Publication Publication Date Title
HK1062923A1 (en) Igf-binding protein-derived peptide
WO2004033481A3 (fr) Peptide ou petite molecule derives d'une proteine de liaison a l'igf
WO2004080405A3 (fr) Peptide ou petite molecule derive d'une proteine de liaison igf
WO2004039956A3 (fr) Compositions et methodes de traitement de maladies liees au systeme immunitaire
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
DE60028970D1 (de) An her2 bindende peptidverbindungen
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2002046222A3 (fr) Compositions et procede de diagnostic de la maladie d'alzheimer
DK1673475T3 (da) Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
WO2006095347A3 (fr) Preparations de vdac1 et leurs methodes d'utilisation pour reguler l'apoptose
WO2004024072A3 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
WO2004081199A3 (fr) Nouvelles compositions et methodes de traitement de troubles du systeme immunitaire
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
CA2505506A1 (fr) Composes utiles pour le diagnostic et le suivi de maladies associees a la formation de fibrilles proteiques amyloides
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
SE0202608D0 (sv) New sequences
WO2003054009A3 (fr) Peptides ayant un effet sur l'apoptose

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150809